La Eficacia de la Suplementación con Probióticos en el Estrés y la Ansiedad (PROfoS)
Eficacia de la Suplementación con Probióticos en el Estrés y la Ansiedad - un Estudio de Intervención Aleatorizado y Controlado con Placebo en Estudiantes Sanos durante el Periodo de Exámenes.
This randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of an 8-week probiotic supplementation (Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 in total daily dose 1 × 10¹⁰ CFU or matching placebo) in reducing perceived stress and anxiety, and improvement related psychological parameters in healthy university students during the examination period. The primary outcome is the change in Perceived Stress Scale (PSS-10) score at week 5 and week 8 of interevention compared to placebo. The secondary outcomes are the changes in DASS-21 subscales (Stress, Anxiety, Depression), State-Trait Anxiety Inventory - State version scale (STAI-S), Sense of Coherence Scale (SOC-29), Pittsburgh Sleep Quality Index (PSQI), self-reported gastrointestinal symptoms (Likert scale) and incidence of adverse events during the 8-week lasting interventional study.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The gut-brain axis enables bidirectional communication between the gastrointestinal tract and the central nervous system. Emerging evidence suggests that selected probiotic strains (psychobiotics) may modulate stress responses and emotional regulation. University examination periods constitute a predictable model of transient psychological stress in otherwise healthy individuals.
This study investigates whether daily supplementation with a probiotic combination of Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 reduces perceived stress and improves related psychological parameters in healthy students exposed to exam-related stress. Two hundred male and female students aged 18-40 years with at least moderate stress and mild anxiety, but without clinical depression, will be enrolled at the Medical University of Lublin, Poland. After providing written informed consent and confirming eligibility criteria, participants will be randomized in a 1:1 ratio to receive either a probiotic formulation containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 (total daily dose of 1 × 10¹⁰ colony-forming units) or a matching placebo.
The investigational product and placebo will be identical in appearance and administered orally once daily (two capsules) for 8 weeks. Randomization will be computer-generated, and both participants and investigators will remain blinded to treatment allocation throughout the study. The intervention will begin approximately six weeks before the first scheduled academic examination. Study assessments will be conducted at baseline, at week 5 (approximately one week before the first examination), and at week 8 (±3 days before a subsequent examination). Psychological and functional parameters will be collected using validated self-report instruments administered electronically, with selected assessments performed during on-site visits. Participants will be asked to maintain their usual diet, physical activity, and caffeine intake during the study period. Safety and tolerability will be monitored throughout the intervention, and adverse events will be recorded using an electronic reporting system with daily reminders.
The study is powered to detect clinically meaningful differences between groups in perceived stress levels and will be analyzed using appropriate covariance-based statistical models adjusted for baseline values and relevant covariates. All participant data will be coded to ensure confidentiality and handled in accordance with applicable data protection regulations.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Emilia Majsiak, Professor of University, PhD
- Número de teléfono: +48667633263
- Correo electrónico: Emilia.Majsiak@umlub.edu.pl
Copia de seguridad de contactos de estudio
- Nombre: Bożena Cukrowska, Prof., MD, PhD
- Número de teléfono: 609447892
- Correo electrónico: bc@nordicbiotic.com
Ubicaciones de estudio
-
-
-
Lublin, Polonia
- Reclutamiento
- University of Lublin, Faculty of Health Sciences
-
Contacto:
- Emilia Majsiak, Prof. PhD
- Número de teléfono: +48 667633263
- Correo electrónico: Emilia.Majsiak@umlub.edu.pl
-
Investigador principal:
- Emilia Majsiak, Prof., PhD
-
Sub-Investigador:
- Renata Markiewicz, PhD
-
Sub-Investigador:
- Mariusz Wysokiński, Prof., PhD
-
Sub-Investigador:
- Wiesław Fidecki, Prof. PhD
-
Sub-Investigador:
- Kinga Zdunek, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female students aged 18-40 years
- At least moderate stress (DASS-21 Stress score ≥10)
- Mild anxiety (DASS-21 Anxiety score 6-13)
- No clinical depression (DASS-21 Depression score ≤9)
- Willingness to maintain usual diet, physical activity, and intake of caffeinated beverages during the study
- Written informed consent
Exclusion Criteria:
- Irritable bowel syndrome (Rome IV criteria) or any chronic intestinal disease (including celiac disease)
- Known food allergies, immunodeficiency disorders, or immunosuppressive treatment
- Antibiotic use within 4 weeks prior to screening
- Any psychiatric illness within the past 5 years
- Any malignant disease or autoimmune or allergic diseases (e.g., atopic dermatitis, asthma)
- Use of systemic psychotropic medications or steroids; use of topical corticosteroid creams within 4 weeks prior to screening
- Pregnancy, breastfeeding, or plans to become pregnant during the study
- Probiotic or prebiotic consumption or planned dietary changes within 4 weeks prior to screening
- Heavy caffeine consumption (>4 cups of 300 mL coffee per day)
- Drug or alcohol addiction or regular use of recreational drugs
- Smoking more than 10 cigarettes per day
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Probiotic
Two capsules containing Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 will be administered orally once daily (total daily dose of 1 × 10¹⁰ colony-forming units) for 8 weeks. |
Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 |
|
Comparador de placebos: Placebo
Maltodextrin will be used as a placebo. The placebo capsules will be identical in appearance to the probiotic capsules and will be administered orally once daily (two capsules) for 8 weeks. |
Maltodextrin |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in perceived stress score
Periodo de tiempo: Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo
|
Perceived stress will be assessed using the 10-Item Perceived Stress Scale (PSS-10), a validated questionnaire measuring the degree to which situations in one's life are appraised as stressful. The total score ranges from 0 to 40, with higher scores indicating higher perceived stress levels (worse outcome). Changes in the total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in total perceived stress score from baseline to week 5 and to week 8 (±3 days) compared to placebo
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in stress, anxiety and depression scores
Periodo de tiempo: Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
Stress, anxiety, and depression will be assessed using the Depression Anxiety Stress Scales - 21 Items (DASS-21). The DASS-21 consists of three subscales (Depression, Anxiety, and Stress), each including 7 items. Scores for each subscale range from 0 to 42 after standard score multiplication, with higher scores indicating greater symptom severity (worse outcome). Changes in the Stress, Anxiety, and Depression subscale scores from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in DASS-21 Stress, Anxiety, and Depression subscale scores from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
|
Change in sleep quality score
Periodo de tiempo: Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire measuring sleep quality over the previous month. The global PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome). Changes in the PSQI global score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in Pittsburgh Sleep Quality Index (PSQI) global score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
|
Change in sense of coherence score
Periodo de tiempo: Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
Sense of coherence will be assessed using the Sense of Coherence Scale - 29 Items (SOC-29), a validated questionnaire measuring psychological resilience and the ability to cope with stress. The total score ranges from 29 to 203, with higher scores indicating a stronger sense of coherence (better outcome). Changes in the SOC-29 total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in Sense of Coherence Scale - 29 Items (SOC-29) total score from baseline to week 5 and week 8 (±3 days) compared to placebo.
|
|
Change in state anxiety score
Periodo de tiempo: Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.
|
State anxiety will be assessed using the State-Trait Anxiety Inventory - State version (STAI-S), a validated questionnaire measuring the current level of anxiety. The STAI-S total score ranges from 20 to 80, with higher scores indicating higher levels of anxiety (worse outcome). Changes in the STAI-S total score from baseline will be analyzed to evaluate the effect of probiotic supplementation. |
Change in State-Trait Anxiety Inventory - State version (STAI-S) total score from baseline to week 8 compared to placebo.
|
|
Change in severity of gastro-intestinal symptoms
Periodo de tiempo: Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo
|
The severitty of gastro-intestinal symptoms will be assessed with the use of 4-point Likert scale (0 - no symptom, 1 - weak, 2 - moderate, 4 - severe). The following symptoms will be assessed: abdominal pain, flatulence, nausea. |
Change from baseline in gastro-intestinal severity score at Week 5 and Week 8 compared to placebo
|
|
Incidence of treatment-emergent adverse events (Safety and Tolerability)
Periodo de tiempo: From baseline through the 8-week intervention period.
|
Safety and tolerability will be assessed by monitoring the incidence of adverse events throughout the study. Adverse events will be self-reported by participants using an electronic reporting platform, which provides daily reminders for study product intake and allows participants to record any symptoms or adverse events experienced during the study period. |
From baseline through the 8-week intervention period.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Emilia Majsiak, Prof. PhD, Medical University of Lublin
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- CT/NB/180/2025/PR-MS
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .